about
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.Chimeric antigen receptor-modified T cells: CD19 and the road beyondPhosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell functionFactors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyThe response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
P50
description
researcher
@en
name
Stanley R Riddell
@en
type
label
Stanley R Riddell
@en
prefLabel
Stanley R Riddell
@en
P31
P496
0000-0002-4688-9920